Brian Skorney
Stock Analyst at Baird
(3.73)
# 766
Out of 5,113 analysts
120
Total ratings
46.51%
Success rate
9.98%
Average return
Main Sectors:
Stocks Rated by Brian Skorney
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MIRM Mirum Pharmaceuticals | Maintains: Outperform | $80 → $88 | $70.28 | +25.21% | 6 | Dec 9, 2025 | |
| ANRO Alto Neuroscience | Maintains: Outperform | $16 → $22 | $19.45 | +13.11% | 4 | Nov 13, 2025 | |
| SRPT Sarepta Therapeutics | Maintains: Neutral | $21 → $15 | $20.34 | -26.25% | 13 | Nov 4, 2025 | |
| CRNX Crinetics Pharmaceuticals | Maintains: Outperform | $58 → $62 | $45.14 | +37.35% | 5 | Sep 26, 2025 | |
| BHVN Biohaven | Maintains: Outperform | $57 → $52 | $11.13 | +367.21% | 4 | Aug 12, 2025 | |
| SLNO Soleno Therapeutics | Maintains: Outperform | $105 → $121 | $48.38 | +150.10% | 5 | Jul 11, 2025 | |
| DYN Dyne Therapeutics | Maintains: Outperform | $46 → $32 | $18.55 | +72.51% | 2 | Jun 18, 2025 | |
| BIIB Biogen | Maintains: Outperform | $300 → $255 | $169.91 | +50.08% | 17 | May 2, 2025 | |
| REGN Regeneron Pharmaceuticals | Maintains: Neutral | $652 → $587 | $748.71 | -21.60% | 15 | Apr 30, 2025 | |
| GILD Gilead Sciences | Maintains: Neutral | $95 → $100 | $121.47 | -17.68% | 3 | Feb 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $30 | $11.38 | +163.62% | 1 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $14 → $5 | $0.12 | +3,945.31% | 4 | Nov 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $26 → $20 | $14.53 | +37.65% | 6 | Nov 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $25 | $11.06 | +126.04% | 1 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Underperform | $215 | $324.42 | -33.73% | 4 | Sep 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $157 → $180 | $141.84 | +26.90% | 4 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $28 | $9.96 | +181.12% | 1 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $34 → $39 | $13.51 | +188.68% | 3 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $63 | $43.23 | +45.73% | 1 | Dec 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $280 → $325 | $447.38 | -27.35% | 14 | May 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $10 | $26.18 | -61.80% | 2 | Aug 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $270 | $0.74 | +36,386.49% | 1 | May 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $18 → $6 | $4.12 | +45.63% | 1 | Feb 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $600 → $300 | $1.15 | +25,986.96% | 3 | May 7, 2018 |
Mirum Pharmaceuticals
Dec 9, 2025
Maintains: Outperform
Price Target: $80 → $88
Current: $70.28
Upside: +25.21%
Alto Neuroscience
Nov 13, 2025
Maintains: Outperform
Price Target: $16 → $22
Current: $19.45
Upside: +13.11%
Sarepta Therapeutics
Nov 4, 2025
Maintains: Neutral
Price Target: $21 → $15
Current: $20.34
Upside: -26.25%
Crinetics Pharmaceuticals
Sep 26, 2025
Maintains: Outperform
Price Target: $58 → $62
Current: $45.14
Upside: +37.35%
Biohaven
Aug 12, 2025
Maintains: Outperform
Price Target: $57 → $52
Current: $11.13
Upside: +367.21%
Soleno Therapeutics
Jul 11, 2025
Maintains: Outperform
Price Target: $105 → $121
Current: $48.38
Upside: +150.10%
Dyne Therapeutics
Jun 18, 2025
Maintains: Outperform
Price Target: $46 → $32
Current: $18.55
Upside: +72.51%
Biogen
May 2, 2025
Maintains: Outperform
Price Target: $300 → $255
Current: $169.91
Upside: +50.08%
Regeneron Pharmaceuticals
Apr 30, 2025
Maintains: Neutral
Price Target: $652 → $587
Current: $748.71
Upside: -21.60%
Gilead Sciences
Feb 12, 2025
Maintains: Neutral
Price Target: $95 → $100
Current: $121.47
Upside: -17.68%
Dec 13, 2024
Initiates: Outperform
Price Target: $30
Current: $11.38
Upside: +163.62%
Nov 29, 2024
Maintains: Outperform
Price Target: $14 → $5
Current: $0.12
Upside: +3,945.31%
Nov 26, 2024
Maintains: Outperform
Price Target: $26 → $20
Current: $14.53
Upside: +37.65%
Oct 31, 2024
Initiates: Outperform
Price Target: $25
Current: $11.06
Upside: +126.04%
Sep 25, 2024
Reiterates: Underperform
Price Target: $215
Current: $324.42
Upside: -33.73%
Aug 2, 2024
Maintains: Outperform
Price Target: $157 → $180
Current: $141.84
Upside: +26.90%
Jun 13, 2024
Initiates: Outperform
Price Target: $28
Current: $9.96
Upside: +181.12%
Mar 6, 2024
Maintains: Outperform
Price Target: $34 → $39
Current: $13.51
Upside: +188.68%
Dec 8, 2023
Initiates: Outperform
Price Target: $63
Current: $43.23
Upside: +45.73%
May 2, 2023
Maintains: Neutral
Price Target: $280 → $325
Current: $447.38
Upside: -27.35%
Aug 3, 2021
Downgrades: Neutral
Price Target: $10
Current: $26.18
Upside: -61.80%
May 20, 2021
Initiates: Outperform
Price Target: $270
Current: $0.74
Upside: +36,386.49%
Feb 26, 2021
Downgrades: Neutral
Price Target: $18 → $6
Current: $4.12
Upside: +45.63%
May 7, 2018
Maintains: Outperform
Price Target: $600 → $300
Current: $1.15
Upside: +25,986.96%